ForCast Orthopedics receives FDA designation for PJI treatment program
Click Here to Manage Email Alerts
Key takeaways:
- ForCast Orthopedics received FDA qualified infectious disease product designation for its FC001 program.
- The program facilitates a targeted antibiotic therapy in patients with periprosthetic joint infection.
ForCast Orthopedics has announced FDA qualified infectious disease product designation for its FC001 periprosthetic joint infection treatment program, according to a press release.
The FC001 program is being developed to facilitate a targeted antibiotic therapy in patients with periprosthetic joint infection, according to the release.
Qualified infectious disease product (QIDP) designation is an FDA incentive offered for the development of antifungal and antibacterial drugs that treat “serious or life-threatening infections,” according to the release.
“We are pleased to receive QIDP designation from the FDA,” Peter Noymer, PhD, executive chair and CEO of ForCast Orthopedics, said in the release. “This represents an important milestone for the company as we progress our lead product through development and toward commercialization,” Noymer added.
“This is an exciting step forward for ForCast, and one that validates our commitment to making better therapies available sooner for PJI patients,” Jared Foran, MD, chief scientific officer and co-founder of ForCast Orthopedics, said in the release.
Read more about
Click Here to Manage Email Alerts